Cancer Family
Malignant Head and Neck Neoplasm
CI-CAN-00000236Explore in graph →
1,432 active trials17 approved drugs142 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000236Explore in graph →
Clinical trials
5,449 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (629)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02369835 | Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy | completed | Phase 3 | 132 | Stanford UniversityOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT04760288 | A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).(AcceleRET-MTC) | withdrawn | Phase 3 | 0 | Hoffmann-La RocheINDUSTRY | 1 | Jan 5, 2024 |
| clinicaltrials |
| NCT00415233 | High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer(HiLo) | unknown | Phase 3 | 438 | University College, LondonOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT06092957 | Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy | recruiting | Phase 3 | 504 | Sun Yat-sen UniversityOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT05125055 | Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC | recruiting | Phase 2 / Phase 3 | 80 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05576272 | A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma | unknown | Phase 2 / Phase 3 | 460 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06102395 | Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC | recruiting | Phase 3 | 272 | Beijing Tongren HospitalOTHER | 1 | Oct 30, 2023 | clinicaltrials |
| NCT06095167 | Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC | not yet recruiting | Phase 3 | 476 | Fujian Cancer HospitalOTHER_GOV | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06082180 | A Prospective, Open-label, Multicenter, Randomized Controlled Phase III Study of Prophylactic Central Neck Dissection in Low-risk Papillary Thyroid Cancer | recruiting | Phase 3 | 1,199 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT01864850 | Non Inferiority Trial of Standard RT Versus Hypofractionated Split Course in Elderly Vulnerable Patients With HNSCC(ELAN-RT) | completed | Phase 3 | 202 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 2 | Sep 22, 2023 | clinicaltrials |
| NCT02741570 | Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck(CheckMate 651) | completed | Phase 3 | 947 | Bristol-Myers SquibbINDUSTRY | 18 | Sep 21, 2023 | clinicaltrials |
| NCT06026878 | GNT Induction Treatment in Locally Advanced NPC | recruiting | Phase 3 | 228 | Air Force Military Medical University, ChinaOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT06016400 | Using Vitamin D to Reduce Oral Mucosal Inflammation in Chemotherapy Patients With Oral Squamous Cell Carcinoma | unknown | Phase 2 / Phase 3 | 412 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT00820248 | Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer | completed | Phase 3 | 320 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 22, 2023 | clinicaltrials |
| NCT05980715 | PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy(HNC-SYSU-003) | recruiting | Phase 3 | 324 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT00047008 | Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer | completed | Phase 3 | 743 | Radiation Therapy Oncology GroupNETWORK | 1 | Jul 7, 2023 | clinicaltrials |
| NCT02578641 | A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients(VANCE) | completed | Phase 3 | 330 | Tessa TherapeuticsINDUSTRY | 5 | Jun 28, 2023 | clinicaltrials |
| NCT00003592 | Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer | completed | Phase 3 | 230 | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 22, 2023 | clinicaltrials |
| NCT01321554 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)(SELECT) | completed | Phase 3 | 392 | Eisai Inc.INDUSTRY | 23 | Jun 22, 2023 | clinicaltrials |
| NCT03919552 | Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 3 | 482 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT00054561 | Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer | completed | Phase 3 | — | Eastern Cooperative Oncology GroupNETWORK | 5 | Jun 15, 2023 | clinicaltrials |
| NCT05877872 | Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma | recruiting | Phase 3 | 424 | Sun Yat-sen UniversityOTHER | 1 | May 26, 2023 | clinicaltrials |
| NCT03700905 | Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy(IMSTAR-HN) | unknown | Phase 3 | 276 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT03306121 | TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 322 | Sun Yat-sen UniversityOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT03321539 | Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma | unknown | Phase 3 | 216 | Sun Yat-sen UniversityOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT05860868 | Two Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 3 | 474 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | May 16, 2023 | clinicaltrials |
| NCT05854849 | Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC | recruiting | Phase 3 | 244 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT04019548 | Assessment of Swallowing Function and Quality of Life in Oropharyngeal Cancer Patients Treated by Chemo-radiotherapy(SwallPEG) | recruiting | Phase 3 | 110 | Jules Bordet InstituteOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT05527470 | Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 3 | 440 | Wei JiangOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05364918 | Clinical Study On Acute Radiotherapy-Induced Oral Mucositis In Patients With Locally Advanced Head And Neck Tumors | completed | Phase 3 | 100 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Apr 24, 2023 | clinicaltrials |
| NCT02940925 | TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma | completed | Phase 3 | 241 | Sun Yat-sen UniversityOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05802290 | NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN(NIVACTOR) | completed | Phase 3 | 124 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT05780294 | A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC | not yet recruiting | Phase 3 | 132 | Sun Yat-sen UniversityOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT04189107 | Postoperative Pain, Why Still in Hospital and DAOH Following TORS for SCCUP & OSAS | completed | Phase 3 | 18 | Rigshospitalet, DenmarkOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT05772208 | Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy | recruiting | Phase 3 | 459 | Fudan UniversityOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT05717764 | Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment | not yet recruiting | Phase 3 | 500 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.INDUSTRY | 0 | Feb 8, 2023 | clinicaltrials |
| NCT04969861 | BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) | terminated | Phase 2 / Phase 3 | 1 | Nektar TherapeuticsINDUSTRY | 4 | Jan 12, 2023 | clinicaltrials |
| NCT05674305 | Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy | recruiting | Phase 3 | 366 | Fudan UniversityOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT01855451 | Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma(HPVOropharynx) | unknown | Phase 3 | 189 | Trans Tasman Radiation Oncology GroupOTHER | 2 | Nov 18, 2022 | clinicaltrials |
| NCT03837808 | Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma | unknown | Phase 3 | 384 | Sun Yat-sen UniversityOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT02460419 | Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma | completed | Phase 3 | 104 | Sun Yat-sen UniversityOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT00274937 | Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer | completed | Phase 3 | 111 | Children's Oncology GroupNETWORK | 3 | Oct 25, 2022 | clinicaltrials |
| NCT05468554 | Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid Cancer(METHYR) | unknown | Phase 3 | 160 | Medical University of BialystokOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT02105636 | Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) | completed | Phase 3 | 361 | Bristol-Myers SquibbINDUSTRY | 15 | Oct 5, 2022 | clinicaltrials |
| NCT00997906 | Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC | unknown | Phase 2 / Phase 3 | 172 | National Cancer Centre, SingaporeOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT05519956 | Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International Guidelines | unknown | Phase 3 | 398 | Fujian Cancer HospitalOTHER_GOV | 0 | Sep 19, 2022 | clinicaltrials |
| NCT01265849 | Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity(IT-MATTERS) | completed | Phase 3 | 928 | CEL-SCI CorporationINDUSTRY | 23 | Aug 19, 2022 | clinicaltrials |
| NCT04898374 | Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma | unknown | Phase 3 | 120 | Kuwait Cancer Control CenterOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT03707509 | Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 3 | 263 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Jan 30, 2024source: clinicaltrials